A phase Ib/II trial of INO-5401 in combination with atezolizumab and INO-9012 in patients with advanced bladder cancer
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Atezolizumab (Primary) ; INO 5401 (Primary) ; INO 9012 (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Inovio Pharmaceuticals
- 16 Oct 2017 Status changed from planning to recruiting, according to an Inovio Pharmaceuticals media release.
- 08 Aug 2017 According to an Inovio Pharmaceuticals media release, the company anticipates to initiate this trial in the second half of 2017.
- 05 Jun 2017 New trial record